“From an imaging point of view, I guess you could consider it as having blockbuster potential, though markets for imaging products tend to be much smaller.”

— Alan Carpenter, vice president of Avid Radiopharmaceuticals, discussing an imaging agent in development for Alzheimer’s disease applications, “Avid leading imaging effort as Alzheimer’s discovery key,” pp. 1, 9.